145 related articles for article (PubMed ID: 15368520)
41. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
42. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection.
Feng IC; Koay LB; Sheu MJ; Kuo HT; Sun CS; Lee C; Chuang WL; Liao SK; Wang SL; Tang LY; Cheng CJ; Tsai SL
J Biomed Sci; 2007 Jan; 14(1):43-57. PubMed ID: 17109186
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
[TBL] [Abstract][Full Text] [Related]
44. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
45. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
46. [Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Zheng JJ; Chen XY; Han ZH; Chen Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):54-6. PubMed ID: 18414702
[TBL] [Abstract][Full Text] [Related]
47. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
Nikolaidis N; Vassiliadis T; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
Clin Transplant; 2005 Jun; 19(3):321-6. PubMed ID: 15877792
[TBL] [Abstract][Full Text] [Related]
48. In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens.
Carotenuto P; Artsen A; Niesters HG; Osterhaus AD; Pontesilli O
J Med Virol; 2009 Feb; 81(2):332-9. PubMed ID: 19107973
[TBL] [Abstract][Full Text] [Related]
49. [A long-term observation and follow-up for patients with HBeAg/Anti-HBe seroconversion after lamivudine treatment].
Wu JL; Li SG; Wen FY; Yang XY; Zhou HJ
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):297-9. PubMed ID: 15850522
[TBL] [Abstract][Full Text] [Related]
50. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
51. [Factors related to the outcome of patients with chronic severe hepatitis B and effectiveness of antivirus therapy].
Wu YZ; Zhao FL; Zhang CZ; Li MH; Xie Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):120-2. PubMed ID: 17653310
[TBL] [Abstract][Full Text] [Related]
52. [Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].
Berak H; Wasilewski M; Horban A; Stańczak JJ; Cybula A
Przegl Epidemiol; 2006; 60(2):247-51. PubMed ID: 16964675
[TBL] [Abstract][Full Text] [Related]
53. Frequencies of epitope-specific cytotoxic T lymphocytes in active chronic viral hepatitis B infection by using MHC class I peptide tetramers.
Wu Y; Zhang J; Chen S; Chen A; Wang L; Li J; Zhao T; Zou L; Tang Y; Tingrong L; Wang F
Immunol Lett; 2004 Apr; 92(3):253-8. PubMed ID: 15081620
[TBL] [Abstract][Full Text] [Related]
54. [Influence of Th1/Th2 balance of chronic hepatitis B patients and its significance after lamivudine therapy].
He DM; Mao Q
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):495. PubMed ID: 15329215
[No Abstract] [Full Text] [Related]
55. [Detection of HBV specific cytotoxic lymphocytes responses in severe hepatitis B patients using MHC-peptide tetramer flow cytometry].
Chen Y; Wu W; Li LJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Sep; 14(9):658-61. PubMed ID: 16995978
[TBL] [Abstract][Full Text] [Related]
56. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia.
Sobao Y; Sugi K; Tomiyama H; Saito S; Fujiyama S; Morimoto M; Hasuike S; Tsubouchi H; Tanaka K; Takiguch M
J Hepatol; 2001 Jun; 34(6):922-9. PubMed ID: 11451178
[TBL] [Abstract][Full Text] [Related]
57. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.
Heathcote J; McHutchison J; Lee S; Tong M; Benner K; Minuk G; Wright T; Fikes J; Livingston B; Sette A; Chestnut R
Hepatology; 1999 Aug; 30(2):531-6. PubMed ID: 10421664
[TBL] [Abstract][Full Text] [Related]
58. [Characteristics of HBcAg(18-27) CTL epitopes of the main epidemic HBV strains in China].
Ma SW; Liang MF; Yu YC; Wang ZH; Zhou B; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2008 Feb; 16(2):93-6. PubMed ID: 18304422
[TBL] [Abstract][Full Text] [Related]
59. Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment.
Malacarne F; Webster GJ; Reignat S; Gotto J; Behboudi S; Burroughs AK; Dusheiko GM; Williams R; Bertoletti A
J Infect Dis; 2003 Feb; 187(4):679-82. PubMed ID: 12599086
[TBL] [Abstract][Full Text] [Related]
60. [Relationship between the HBV core gene mutation and the cellular immunity in host].
Li J; Zhu LM; Liang SR; Li ST; Xu J
Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):533-5. PubMed ID: 14552712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
